Cite
Li J, Hlavka-Zhang J, Shrimp JH, et al. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-20-1771.
Li, J., Hlavka-Zhang, J., Shrimp, J. H., Piper, C., Dupere-Richer, D., Roth, J. S., Jing, D., Casellas Roman, H. L., Troche, C., Swaroop, A., Kulis, M., Oyer, J. A., Will, C. M., Shen, M., Riva, A., Bennett, R. L., Ferrando, A. A., Hall, M. D., Lock, R. B., & Licht, J. D. (2021). PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-20-1771
Li, Jianping, et al. "PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-20-1771
Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupere-Richer D, Roth JS, Jing D, Casellas Roman HL, Troche C, Swaroop A, Kulis M, Oyer JA, Will CM, Shen M, Riva A, Bennett RL, Ferrando AA, Hall MD, Lock RB, Licht JD. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discov. 2021 Aug 20; doi: 10.1158/2159-8290.CD-20-1771. Epub 2021 Aug 20. PMID: 34417224.
Copy
Download .nbib